Grundläggande statistik
| LEI | 549300P7MGHAVZCM1N34 |
| CIK | 1602078 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nemaura Medical Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 26, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 1, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer Id |
|
| July 1, 2024 |
NEMAURA MEDICAL INC. (Name of Registrant as Specified in Charter) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D. |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement NEMAURA MEDICAL INC |
|
| May 17, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 9, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer Id |
|
| April 22, 2024 |
Exhibit 3.1 |
|
| April 22, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 28, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement NEMAURA MEDICAL INC |
|
| April 10, 2024 |
Exchange Agreement Dated as of April 3, 2024 Exhibit 10.1 Exchange Agreement Dated as of April 3, 2024 This Exchange Agreement (together with the exhibits and other attachments hereto, this “Agreement”) is entered into as of the date first set forth above (the “Closing Date”) by and between Nemaura Medical Inc., a Nevada corporation (the “Company”), Dermal Diagnostics Limited, an England and Wales corporation (“Dermal Diagnostics”), Trial Cl |
|
| April 10, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 29, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| February 26, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders sSECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 26, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| February 14, 2024 |
NMRD / Nemaura Medical Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G 1 alyeska-nmrd123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nemaura Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640442208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Med |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| January 3, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 3, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| January 3, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 3, 2024 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| January 3, 2024 |
Important Update on Listing Status and Strategic Direction Exhibit 99.1 Important Update on Listing Status and Strategic Direction Loughborough, UK, January 3, 2024 (GLOBE NEWSWIRE) – Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital |
|
| December 13, 2023 |
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision Exhibit 99.1 Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision Loughborough, UK, December 13, 2023 (GLOBE NEWSWIRE) – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pu |
|
| December 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): December 13, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [X] Preliminary Proxy Statement [] Confidential, for |
|
| November 21, 2023 |
Exhibit 10.3 Security Agreement This Security Agreement (this “Agreement”), dated as of November 14, 2023, is executed by Nemaura Medical Inc., a Nevada corporation (“Nemaura”), Dermal Diagnostics Limited, a company incorporated in England and Wales (company no. 6795555) (“Dermal Diagnostics”), and Trial Clinic Limited, a company incorporated in England and Wales (company no. 7490577) (“Trial Clin |
|
| November 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 16, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 21, 2023 |
Exhibit 10.1 Line of Credit Agreement This Line of Credit Agreement (this “Agreement”), dated as of November 14, 2023, is entered into by and among Nemaura Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited, an England and Wales corporation (“Dermal Diagnostics”), Trial Clinic Limited, an England and Wales corporation (“Trial Clinic”, and together with Dermal Diagnostics an |
|
| November 21, 2023 |
Exhibit 10.2 Secured Promissory Note Effective Date: November 14, 2023 Up to $10,000,000.00 FOR VALUE RECEIVED, Nemaura Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited, an England and Wales corporation (“Dermal Diagnostics”), and Trial Clinic Limited, an England and Wales corporation (“Trial Clinic,” and together with Dermal Diagnostics and Company, “Borrower”), jointly |
|
| November 21, 2023 |
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth Exhibit 99.1 Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth Loughborough, UK, November 21, 2023 (GLOBE NEWSWIRE) – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 mill |
|
| November 14, 2023 |
Exhibit 99.1 Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, 14th November 2023. Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced t |
|
| November 14, 2023 |
Exhibit 99.1 Corporate Presentation Sidoti Micro Cap Conference Dr Faz Chowdhury, CEO 15 th November 2023 Nasdaq: NMRD Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified |
|
| November 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 14, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 14, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 13, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 13, 2023 |
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update Exhibit 99.1 Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update Loughborough, England, 13 Nov, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Me |
|
| October 12, 2023 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): October 10, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| October 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): October 03, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| September 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 14, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 14, 2023 |
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process Exhibit 99.1 Nemaura Medical Provides Update on Nasdaq Compliance Status and Process LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) - Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regardi |
|
| September 13, 2023 |
Exhibit 99.1 Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program LOUGHBOROUGH, Sep. 13, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supportin |
|
| September 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 13, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 11, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 11, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 11, 2023 |
Nemaura Medical, Inc. 4,796,206 Shares of Common Stock Filed Pursuant to Rule 424(b)(8) Registration No. 333-270511 Nemaura Medical, Inc. 4,796,206 Shares of Common Stock This prospectus covers the sale of an aggregate of 4,796,206 shares (the “shares”) of our common stock, $0.001 par value per share (the “common stock”), by two selling stockholders identified in this prospectus (collectively with any of the holder’s transferees, pledgees, donees or s |
|
| September 11, 2023 |
Nemaura Medical Completes 100 Patient Study for sugarBEAT Exhibit 99.1 Nemaura Medical Completes 100 Patient Study for sugarBEATÒ 24-hour Wear and Reports Interim Results LOUGHBOROUGH, September 11, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized diabetes management and metabolic healt |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| August 17, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): August 17, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| August 17, 2023 |
Nemaura Medical Announces SFDA Approval of sugarBEAT Exhibit 99.1 Nemaura Medical Announces SFDA Approval of sugarBEATÒ Loughborough, England, August 17, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical |
|
| August 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): August 14, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| August 14, 2023 |
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update Exhibit 99.1 Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update Loughborough, England, August 14, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, tod |
|
| August 11, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): August 11, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| August 11, 2023 |
Nemaura Medical Secures $6.5m in Non-Dilutive Funding Exhibit 99.1 Nemaura Medical Secures $6.5m in Non-Dilutive Funding Loughborough, England, August 11, 2023 (GLOBE NEWSWIRE) - Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [X] Preliminary Proxy Statement [] Confidential, for |
|
| August 3, 2023 |
As filed with the Securities and Exchange Commission on August 3, 2023 As filed with the Securities and Exchange Commission on August 3, 2023 Registration No. |
|
| July 17, 2023 |
EXHIBIT 21.1 SUBSIDIARIES Entity Name Jurisdiction of Incorporation or Organization Dermal Diagnostics (Holdings) Limited England and Wales Dermal Diagnostics Limited England and Wales Trial Clinic Limited England and Wales |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————— FORM 10-K/A —————— x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38355 NEMAURA MEDICA |
|
| July 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 14, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| July 14, 2023 |
Exhibit 99.1 Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023 Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————— FORM 10-K —————— x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38355 NEMAURA MEDICAL |
|
| July 13, 2023 |
EXHIBIT 21.1 SUBSIDIARIES Entity Name Jurisdiction of Incorporation or Organization Dermal Diagnostics (Holdings) Limited England and Wales Dermal Diagnostics Limited England and Wales Trial Clinic Limited England and Wales |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38355 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐Form 10-Q ☐ Form 10-D ☐ Form ☐ N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Repo |
|
| June 27, 2023 |
EXHIBIT 99.1 Nemaura Medical Scales-Up Pilot Expansion of proBEATTM; 56 Corporations in the USA signed up for pilots, in June 2023 LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT™ |
|
| June 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): June 27, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| May 31, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 25, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer I |
|
| May 15, 2023 |
Nemaura Medical, Inc. 4,796,206 Shares of Common Stock 424B4 1 nmrd424b.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration No. 333-270511 Nemaura Medical, Inc. 4,796,206 Shares of Common Stock This prospectus covers the sale of an aggregate of 4,796,206 shares (the “shares”) of our common stock, $0.001 par value per share (the “common stock”), by two selling stockholders identified in this prospectus (collectively with any of the holder’s transfe |
|
| May 11, 2023 |
NEMAURA MEDICAL, INC. 57 West 57th Street New York, New York 10019 May 11, 2023 Correspondence NEMAURA MEDICAL, INC. 57 West 57th Street New York, New York 10019 May 11, 2023 CORRESPONDENCE FILING VIA EDGAR Ms. Abby Adams Office of Industrial Applications and Services U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Nemaura Medical, Inc. Registration Statement Filed on Form S-1 File No. 333-270511 Dear Ms. Adams: On behalf of Nemaura Medic |
|
| May 10, 2023 |
CORRESP 1 filename1.htm Correspondence ANTHONY L.G., PLLC laura aNTHONy, esq JOHN CACOMANOLIS, ESQ* CHAD FRIEND, ESQ, LLM SVETLANA ROVENSKAYA, ESQ** WWW.ANTHONYPLLC.COM WWW.SECURITIESLAWBLOG.COM WWW.LAWCAST.COM OF COUNSEL: Jessica Haggard, esq. *** MICHAEL R. GEROE, ESQ, CIPP/US**** CRAIG D. LINDER, ESQ***** PETER P. LINDLEY, ESQ, CPA, MBA john lowy, esq.****** STUART REED, ESQ LAZARUS ROTHSTEIN, |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement NEMAURA MEDICAL, IN |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 18, 2023 |
Correspondence ANTHONY L.G., PLLC laura aNTHONy, esq JOHN CACOMANOLIS, ESQ* CHAD FRIEND, ESQ, LLM SVETLANA ROVENSKAYA, ESQ** WWW.ANTHONYPLLC.COM WWW.SECURITIESLAWBLOG.COM WWW.LAWCAST.COM OF COUNSEL: Jessica Haggard, esq. *** MICHAEL R. GEROE, ESQ, CIPP/US**** CRAIG D. LINDER, ESQ***** PETER P. LINDLEY, ESQ, CPA, MBA john lowy, esq.****** STUART REED, ESQ LAZARUS ROTHSTEIN, ESQ. Harris Tulchin, Esq |
|
| April 7, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): April 3, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [X] Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement NEMAURA MEDICAL, |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 13, 2023 Registration No. |
|
| March 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) NEMAURA MEDICAL, INC. |
|
| March 9, 2023 |
Nemaura Medical Announces Receipt of Notice from Nasdaq Exhibit 99.1 Nemaura Medical Announces Receipt of Notice from Nasdaq LOUGHBOROUGH, Mar. 9, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced that on February 23, 2023, the Co |
|
| March 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 23, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| March 1, 2023 |
Letter, dated March 1, 2023, from Mayer Hoffman McCann P.C. addressed to the Commission. Exhibit 16.1 March 1, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read item 4.01 of Nemaura Medical, Inc.’s Form 8-K dated February 23, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. With respect to all other matters, we have no basis to agree or disagree with the statements made by the |
|
| March 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 23, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3 |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Med |
|
| February 23, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 27, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| February 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT (Amendment No. 1) Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 17, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission Fil |
|
| February 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 17, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38355 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form ☐ N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition |
|
| January 31, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2023, between Nemaura Medical Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| January 31, 2023 |
Exhibit 99.1 Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) - Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight |
|
| January 31, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 27, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| January 31, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 31, 2023 |
NEMAURA MEDICAL INC. 4,796,206 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(5) Registration No. 333-263618 Prospectus Supplement (to Prospectus dated March 28, 2022) NEMAURA MEDICAL INC. 4,796,206 SHARES OF COMMON STOCK Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to 4,796,206 shares of our common stock, par value $0.001 per share (the “common stock”). The shares of common stock are being sold dir |
|
| January 31, 2023 |
Exhibit 10.2 NEMAURA MEDICAL INC. 4,796,206 Shares of Common Stock Warrants to Purchase up to 4,796,206 Shares of Common Stock PLACEMENT AGENT AGREEMENT January 27, 2023 EF Hutton, division of Benchmark Investments, LLC 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”) Nemaura Medical Inc., a Nevada corporati |
|
| January 26, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 26, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| January 26, 2023 |
Exhibit 99.1 Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet Nemaura to integrate its proBEATTM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. LOUGHBOROUGH, Jan. 26, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercial |
|
| January 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 25, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| January 25, 2023 |
Corporate Presentation 25 th January 2023 Nasdaq : NMRD Exhibit 99.1 Corporate Presentation 25 th January 2023 Nasdaq : NMRD Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan |
|
| January 24, 2023 |
Exhibit 99.1 Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants Average weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients LOUGHBOROUGH, Jan. 24, 2023 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on devel |
|
| January 24, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 24, 2023 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Me |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 14, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 14, 2022 |
Secured Promissory Note, dated as of May 20, 2022, issued by Nemaura Medical Inc. Exhibit 10.3 Secured Promissory Note Effective Date: May 20, 2022 U.S. $6,015,000.00 FOR VALUE RECEIVED, Nemaura Medical Inc., a Nevada corporation (?Company?), Dermal Diagnostics Limited, an England and Wales corporation (?Dermal Diagnostics?), and Trial Clinic Limited, an England and Wales corporation (?Trial Clinic,? and together with Dermal Diagnostics, ?Borrower?), jointly and severally promi |
|
| November 14, 2022 |
Exhibit 10.4 Security Agreement This Security Agreement (this ?Agreement?), dated as of May 20, 2022, is executed by Nemaura Medical Inc., a Nevada corporation (?Nemaura?), Dermal Diagnostics Limited, a company incorporated in England and Wales (company no. 6795555) (?Dermal Diagnostics?), and Trial Clinic Limited, a company incorporated in England and Wales (company no. 7490577) (?Trial Clinic,? |
|
| November 14, 2022 |
Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update Exhibit 99.1 Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update Loughborough, England – November 15, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, |
|
| November 14, 2022 |
Exhibit 10.2 Note Purchase Agreement This Note Purchase Agreement (this ?Agreement?), dated as of May 20, 2022, is entered into by and among Nemaura Medical Inc., a Nevada corporation (?Company?), Dermal Diagnostics Limited, an England and Wales corporation (?Dermal Diagnostics?), Trial Clinic Limited, an England and Wales corporation (?Trial Clinic?, and together with Dermal Diagnostics and Compa |
|
| October 26, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): October 21, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| October 26, 2022 |
Exhibit 10.1 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this ?Amendment?) is entered into as of October 21, 2022, by and among Uptown Capital, LLC, a Utah limited liability company (?Lender?), Nemaura Medical Inc., a Nevada corporation (?Nemaura?), Dermal Diagnostics Limited, a company incorporated in England and Wales (company no. 6795555) (?Dermal Diagnostics |
|
| October 12, 2022 |
Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA Exhibit 99.1 Nemaura Receives Provisional Purchase Order from Middle East Licensee TPMENA LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) - Nemaura Medical, Inc. (NASDAQ: NMRD)(?Nemaura? or the ?Company?), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced it h |
|
| October 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): October 12, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| July 8, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 1, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer I |
|
| July 1, 2022 |
EXHIBIT 99.1 Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022 Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) ? Nemaura Medical, Inc. (Nasdaq: NMRD) (?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle |
|
| July 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): June 30, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ????? FORM 10-K ?????? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38355 NEMAURA MEDICAL |
|
| June 29, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21.1 SUBSIDIARIES Entity Name Jurisdiction of Incorporation or Organization Dermal Diagnostics (Holdings) Limited England and Wales Dermal Diagnostics Limited England and Wales Trial Clinic Limited England and Wales |
|
| April 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): April 1, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| April 1, 2022 |
NEMAURA MEDICAL INC. Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263618 PROSPECTUS SUPPLEMENT (To Prospectus dated March 28, 2022) NEMAURA MEDICAL INC. $3,000,000 Shares of Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or the sales agent or Wainwright, dated as of July 23, 2021 and amended as of April 1, 2022, relating to the o |
|
| April 1, 2022 |
Exhibit 10.1 April 1, 2022 Nemaura Medical Inc. 57 West 57th Street New York, NY 10019 Attention: Dr. Dewan F.H. Chowdhury, President and Chief Executive Officer Dear Dr. Chowdhury: Reference is made to the At The Market Offering Agreement, dated as of July 23, 2021 (the ?ATM Agreement?), between Nemaura Medical Inc. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?). This letter (the ? |
|
| March 24, 2022 |
NEMAURA MEDICAL INC. 57 West 57th Street New York, NY 10019 (646) 416-8000 Correspondence NEMAURA MEDICAL INC. 57 West 57th Street New York, NY 10019 (646) 416-8000 March 24, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Jane Park Re: Nemaura Medical Inc. Registration Statement on Form S-3 File Number 333-263618 REQUEST FOR ACCELERATION OF EFFECTIVENESS Ms. Park: In accorda |
|
| March 16, 2022 |
As filed with the Securities and Exchange Commission on March 16, 2022 As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. |
|
| March 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nemaura Medical Inc. |
|
| March 16, 2022 |
EXHIBIT 4.4 NEMAURA MEDICAL, INC. Issuer AND [TRUSTEE] Trustee INDENTURE Dated as of [?], 20[?] Senior Debt Securities ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee?s Certificate. 7 Section 2.03 Deno |
|
| March 16, 2022 |
EXHIBIT 4.5 NEMAURA MEDICAL, INC. Issuer AND [TRUSTEE] Trustee INDENTURE Dated as of [?], 20[?] Subordinated Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certific |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Med |
|
| February 11, 2022 |
Corporate Presentation 11 th February 2022 Nasdaq : NMRD Corporate Presentation 11 th February 2022 Nasdaq : NMRD Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. |
|
| February 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 11, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| January 10, 2022 |
Exhibit 99.2 H.C. WAINWRIGHT BIOCONNECT CONFERENCE JANUARY 10 - 13, 2022, VIRTUAL CONFERENCE Dr Faz Chowdhury, CEO Nasdaq : NMRD Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies, can sometimes be |
|
| January 10, 2022 |
Statement of Main Terms of Employment dated January 5, 2022 with Arash Ghadar. Exhibit 10.1 STATEMENT OF MAIN TERMS OF EMPLOYMENT This Statement, together with the Employee Handbook, forms part of your Contract of Employment (except where the contrary is expressly stated) and sets out particulars of the main terms on which Dermal Diagnostics Limited (the Company), Advanced Technology Centre, Loughborough University Science & Enterprise Parks, 5 Oakwood Drive, Loughborough, L |
|
| January 10, 2022 |
Nemaura Medical Appoints Dr Arash Ghadar as Chief Operating Officer Exhibit 99.1 Nemaura Medical Appoints Dr Arash Ghadar as Chief Operating Officer Loughborough, England ? January 10, 2022 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD)(?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the appointment |
|
| January 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): January 5, 2022 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| December 7, 2021 |
Benzinga Global Small Cap Conference 8 th December 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Exhibit 99.1 Benzinga Global Small Cap Conference 8 th December 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies, can sometimes be identified by use of ter |
|
| December 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): December 7, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employ |
|
| November 18, 2021 |
Alliance Bernstein CGM Disruptors Conference 19 th November 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Exhibit 99.1 Alliance Bernstein CGM Disruptors Conference 19 th November 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies, can sometimes be identified by use |
|
| November 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 18, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): November 15, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Emplo |
|
| November 15, 2021 |
Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Nemaura Medical Announces Fiscal Second Quarter 2022 Financial Results and Provides Business Update Loughborough, England ? November 15, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (Nasdaq: NMRD) (?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching p |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Me |
|
| September 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 24, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 30, 2021 |
Exhibit 10.1 (1) NEMAURA MEDICAL INC. and (2) MYSUGARWATCH DUOPACK LIMITED LICENCE, SUPPLY AND DISTRIBUTION AGREEMENT 1 Definitions 4 2 Interpretation 6 3 Appointment 7 4 Supply of Products, Forecasting & Orders 8 5 Undertakings 9 6 Specifications and Regulatory Matters 10 7 Title, Risk, Shipment, Delivery And Acceptance 11 8 Prices & Payment 13 9 Limitation Of Liability 14 10 Freedom to Contract |
|
| September 29, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 29, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 29, 2021 |
Nemaura Medical Launches Beta Version of Its Metabolic Health Program Exhibit 99.1 Nemaura Medical Launches Beta Version of Its Metabolic Health Program MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial, multibillion-dollar market opportunity in the healthcare arena LOUGHBOROUGH, England ? Sept. 29, 2021 (GlobeNewswire) - via InvestorWire - Nemaura Medical, Inc. (NASDAQ: NMRD) (?Nemaura? or ?the Company?), a medical techno |
|
| September 28, 2021 |
Exhibit 99.1 BENZINGA HEALTHCARE SMALL CAP INVESTMENT CONFERENCE 29 th September 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies can sometimes be identified |
|
| September 28, 2021 |
Exhibit 99.2 Nemaura Medical Announces Commercial Agreement with UK Licensee Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up Loughborough, England ? September 27, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD)(?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic d |
|
| September 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 27, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 17, 2021 |
Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board Exhibit 99.1 Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board Loughborough, England ? September 17, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD)(?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that Dr |
|
| September 17, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 17, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| September 10, 2021 |
Exhibit 99.1 H.C. Wainwright 23 rd Annual Global Investment Conference 13 - 15 September 2021 Dr Faz Chowdhury, CEO Nasdaq : NMRD Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies, can sometimes be i |
|
| September 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): September 10, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| August 26, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 NEMAURA MEDICAL INC. |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical |
|
| August 16, 2021 |
Exhibit 99.1 Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021 Loughborough, England ? August 16, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (Nasdaq: NMRD) (?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized li |
|
| August 16, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 NEMAURA MEDICAL INC. |
|
| July 26, 2021 |
Corporate Presentation July 2021 Nasdaq : NMRD Exhibit 99.1 Corporate Presentation July 2021 Nasdaq : NMRD Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties . These forward - looking statements, such as statements about Nemaura?s short - term and long - term growth strategies, can sometimes be identified by use of terms such as ?intend,? ?expect,? ?plan,? ?estima |
|
| July 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 26, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| July 23, 2021 |
NEMAURA MEDICAL INC. Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-230535 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2019) NEMAURA MEDICAL INC. $100,000,000 Shares of Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or the sales agent or Wainwright, dated as of July 23, 2021, relating to the offer and sale of shares of our |
|
| July 23, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 23, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| July 23, 2021 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 23, 2021 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Nemaura Medical Inc., a corporation organized under the laws of Nevada (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. Definitions. The terms that follow, when used in this Agre |
|
| July 13, 2021 |
Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 NEMAURA MEDICAL INC. |
|
| June 30, 2021 |
Exhibit 99.1 Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2021 Loughborough, England, June 30, 2021 ? Nemaura Medical Inc. (NASDAQ: NMRD) (?Nemaura?), a medical technology company commercializing sugarBEAT?, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT?diabetes, a health subscription service designed to help pe |
|
| June 29, 2021 |
EXHIBIT 21.1 SUBSIDIARIES Entity Name Jurisdiction of Incorporation or Organization Region Green Limited British Virgin Islands Dermal Diagnostics (Holdings) Limited England and Wales Dermal Diagnostics Limited England and Wales Trial Clinic Limited England and Wales |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ????? FORM 10-K ?????? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38355 NEMAURA MEDICAL |
|
| June 29, 2021 |
Description of Registrant’s Securities Exhibit 4.3 Description of Registrant?s Securities. Capital Stock General The following descriptions of common and preferred stock summarizes the material terms and provisions of the Company?s common stock and preferred stock, but is not intended to be complete. For the full terms of the Company?s common and preferred stock, please refer to the Company?s articles of incorporation, as amended from |
|
| May 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 NEMAURA MEDICAL INC. |
|
| May 14, 2021 |
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation Benzinga Global Small Cap Conference Dr Faz Chowdhury, CEO 14 th May 2021 Nasdaq : NMRD Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth st |
|
| May 5, 2021 |
Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors Exhibit 99.1 Nemaura Medical Announces Order for 200,000 sugarBEAT? Sensors Based on the success of the soft launch in the U.K., the Company is advancing discussions for joint launches in Germany, Saudi Arabia and UAE Loughborough, England ? May 5, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD) (?Nemaura? or the ?Company?), a medical technology company focused on developing and commer |
|
| May 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 NEMAURA MEDICAL INC. |
|
| April 28, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition 8-K 1 nmra8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in its charter) Nevada 001-38355 46-5027260 (State or other jurisdiction of incorpor |
|
| April 13, 2021 |
Exhibit 99.1 Nemaura Medical Launches BEAT?diabetes Smartphone App on Android and iOS Platforms; Begins Pilot Distribution of proBEAT? Sensors Loughborough, England ? April 13, 2021 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD) (?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting person |
|
| April 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 NEMAURA MEDICAL INC. |
|
| April 7, 2021 |
Corporate Presentation Nasdaq: NMRD April 2021 Exhibit 99.1 Corporate Presentation Nasdaq: NMRD April 2021 Forward Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimat |
|
| April 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2021 NEMAURA MEDICAL INC. |
|
| March 15, 2021 |
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation Maxim Group Emerging Growth Virtual Conference Dr Faz Chowdhury, CEO M arch 17 - 18, 2021 Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term gro |
|
| March 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 NEMAURA MEDICAL INC. |
|
| March 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2021 NEMAURA MEDICAL INC. |
|
| March 5, 2021 |
Exhibit 99.1 Corporate Presentation H.C.WAINWRIGHT & CO Global Life Sciences Conference Dr Faz Chowdhury, CEO M arch 9 - 10, 2021 Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Med |
|
| February 11, 2021 |
Nemaura Medical Secures $20 Million Non-Dilutive Loan to Accelerate Business Growth Exhibit 99.1 Nemaura Medical Secures $20 Million Non-Dilutive Loan to Accelerate Business Growth Loughborough, England – February 11, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announc |
|
| February 11, 2021 |
Security Agreement between Nemaura Medical, Inc. and Uptown Capital, LLC dated February 8, 2021. Exhibit 10.3 Security Agreement This Security Agreement (this “Agreement”), dated as of February 8, 2021, is executed by Nemaura Medical Inc., a Nevada corporation (“Nemaura”), Dermal Diagnostics Limited, a company incorporated in England and Wales (company no. 6795555) (“Dermal Diagnostics”), and Trial Clinic Limited, a company incorporated in England and Wales (company no. 7490577) (“Trial Clini |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 NEMAURA MEDICAL INC. |
|
| February 11, 2021 |
Exhibit 10.2 Secured Promissory Note Effective Date: February 8, 2021 U.S. $24,015,000.00 FOR VALUE RECEIVED, Nemaura Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited, an England and Wales corporation (“Dermal Diagnostics”), and Trial Clinic Limited, an England and Wales corporation (“Trial Clinic,” and together with Dermal Diagnostics, “Borrower”), jointly and severally |
|
| February 11, 2021 |
Note Purchase Agreement between Nemaura Medical, Inc. and Uptown Capital, LLC dated February 8, 2021 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Note Purchase Agreement This Note Purchase Agreement (this “Agreement”), dated as of February 8, 2021, is entered into by and among Nemaura Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited, an En |
|
| January 12, 2021 |
Exhibit 99.1 Corporate Presentation H.C.WAINWRIGHT & CO BIOCONNECT 2021 Conference Dr Faz Chowdhury, CEO January 11 - 14, 2021 Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be |
|
| January 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 nmra8k-011121.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 NEMAURA MEDICAL INC. (Exact name of registrant as specified in its charter) Nevada 001-38355 46-5027260 (State or other jurisdiction of |
|
| November 17, 2020 |
Exhibit 99.1 Nemaura Medical Launches BEATTM diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website Loughborough, England – November 17, 2020 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized life |
|
| November 17, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2020 NEMAURA MEDICAL INC. |
|
| November 16, 2020 |
Exhibit 99.1 Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update Loughborough, England ? November 16, 2020 (GlobeNewswire) ? Nemaura Medical, Inc. (NASDAQ: NMRD)(?Nemaura? or the ?Company?), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifesty |
|
| November 16, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 NEMAURA MEDICAL INC. |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical |
|
| November 2, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 NEMAURA MEDICAL INC. |
|
| November 2, 2020 |
Exhibit 10.1 HEALTHIMATION LICENSE AGREEMENT This Healthimation License Agreement (“Agreement”), dated as of September 16, 2020 (the “Effective Date”), is by and between Healthimation, LLC, a Delaware limited liability company, with offices located at 59 Sagamore Street, Dorchester, MA,02125 (“Licensor”) and Nemaura Medical Inc. a Nevada corporation, with offices located at Advanced technology Cen |
|
| November 2, 2020 |
Exhibit 10.2 SCHEDULE 4 TERRITORY The Licensee shall have a license grant in all territories outside of the USA under the Agreement. In the USA Healthimation and Nemaura shall work jointly to deliver a revised version of the WhyWait program in conjunction with Nemaura’s proBEAT product and service offering. License extended on October 23, 2020 to include the territory rights for North America/Unit |
|
| September 21, 2020 |
Employment Agreement between Nemaura Medical, Inc. and Justin Mclarney dated September 15, 2020 Exhibit 10.1 Dated:15th September 2020 1 Dermal Diagnostics Limited 2 Justin Mclarney Employment agreement Table of contents 1 Definitions 1 2 Duration of employment 2 3 Period continuously employed 2 4 Former contracts 2 5 Job title [and description] 2 6 Promotion and protection of our interests 3 7 Place of work 4 8 Normal hours of work 4 9 Pay 4 10 Pension and contracting out certificate 4 11 E |
|
| September 21, 2020 |
Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer Exhibit 99.1 Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer LOUGHBOROUGH, England - September 18, 2020 - Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 NEMAURA MEDICAL INC. |
|
| September 15, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 NEMAURA MEDICAL INC. |
|
| September 15, 2020 |
Presentation of the registrant dated September 2020. Exhibit 99.1 |
|
| August 19, 2020 |
Exhibit 99.1 August 19, 2020 Nemaura Medical issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients Loughborough, England, August 19, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-in |
|
| August 19, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 NEMAURA MEDICAL INC. |
|
| August 19, 2020 |
Exhibit 99.2 Better Diagnostics for Life Continuous Glucose Monitoring in Hospitalised and Quarantined Patients with COVID - 19 August 2020 2 SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS • • This presentation may contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as ame nded, and Section 21E of the Securities Exchange Act of 1934, as amende |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. |
|
| August 10, 2020 |
Termination of a Material Definitive Agreement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): August 8, 2020 NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| July 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 28, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| July 30, 2020 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Nemaura Medical Inc. Warrant Shares: [ Issue Date: [, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. ( |
|
| July 30, 2020 |
Exhibit 10.1 July 28, 2020 Nemaura Medical, Inc. 57 West 57th Street Manhattan, NY New York, NY 10022 Attn: Dewan F. H. Chowdhury Dear Mr. Chowdhury: This letter (the “Agreement”) constitutes the agreement between Kingswood Capital Markets a division of Benchmark Investments, Inc. (“Kingswood” or the “Placement Agent”) and Nemaura Medical, Inc., a company incorporated under the laws of the State o |
|
| July 30, 2020 |
Exhibit 10.2 NEMAURA MEDICAL INC. and NEVADA AGENCY AND TRANSFER COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of July 30, 2020 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of July 30, 2020 (“Agreement”), between Nemaura Medical Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Nevada Agency and Transfer Company (the “Warrant Agen |
|
| July 30, 2020 |
Nemaura Announces Correction and Pricing of Public Offering Exhibit 99.1 Nemaura Announces Correction and Pricing of Public Offering Loughborough, England, July 28, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with B |
|
| July 28, 2020 |
As Filed Pursuant to Rule 424(b)(5) Registration No. 333-230535 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 8, 2019) NEMAURA MEDICAL INC. 1,586,206 Shares of Common Stock Warrants to Purchase up to 793,103 Shares of Common Stock We are offering 1,586,206 shares of our common stock, par value $0.001 per share, and warrants to purchase up to 793,103 shares of our common stock (each a “Warrant”) |
|
| July 28, 2020 |
SUBJECT TO COMPLETION, DATED JULY 27, 2020 As Filed Pursuant to Rule 424(b)(5) Registration No. 333-230535 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securitie |
|
| July 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2020 NEMAURA MEDICAL INC. |
|
| July 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 NEMAURA MEDICAL INC. |
|
| July 14, 2020 |
Exhibit 99.2 Better Diagnostics for Life BEAT™ Continuous non - invasive Lactate Monitoring In Critical Care and Monitoring Disease Progression in Covid - 19 July 2020 2 Author Dr Moiz Khan, Pharm.D , MBA 3 Overview Continuous Lactate monitoring has Potential in Medical and non Medical Applications. Medical Field - Recent reports of elevated Lactate levels in Covid - 19 patients - Critical Care mo |
|
| July 14, 2020 |
Exhibit 99.1 JULY 14, 2020 Nemaura Medical Evaluates New Applications for Continuous Lactate Monitoring using its BEAT™ platform Loughborough, England, July 14, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and fle |
|
| July 7, 2020 |
Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA Exhibit 99.1 Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. ET to Discuss Commercialization Progress Loughborough, England, July 07, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices a |
|
| July 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): July 7, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer I |
|
| June 30, 2020 |
EXHIBIT 21.1 SUBSIDIARIES Region Green Limited Dermal Diagnostics (Holdings) Limited Dermal Diagnostics Limited Trial Clinic Limited |
|
| June 30, 2020 |
Exhibit 99.1 Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020 LOUGHBOROUGH, England, June 30, 2020-Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help peop |
|
| June 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): June 30, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————— FORM 10-K —————— ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38355 NEMAURA MEDICAL |
|
| June 30, 2020 |
Description of Registrant’s Securities Exhibit 4.3 Description of Registrant’s Securities. Capital Stock General The following descriptions of common and preferred stock summarizes the material terms and provisions of the Company’s common stock and preferred stock, but is not intended to be complete. For the full terms of the Company’s common and preferred stock, please refer to the Company’s articles of incorporation, as amended from |
|
| May 19, 2020 |
8-K 1 nmra8k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 18, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission Fi |
|
| May 15, 2020 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 15, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer I |
|
| May 11, 2020 |
Better Diagnostics for Life Management of Type 2 Diabetes using non - invasive CGM 11 th May 2020 Exhibit 99.2 Better Diagnostics for Life Management of Type 2 Diabetes using non - invasive CGM 11 th May 2020 2 Authors Dr R K Ibrahim Head of data analytics Mr Steve Willmor Head of Regulatory 3 Summary of Presentation There is compelling evidence suggesting Type 2 diabetes may be managed by use of a Continuous Glucose Monitor (CGM) on non - consecutive days, leading to clinically significant ou |
|
| May 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 11, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer I |
|
| May 11, 2020 |
Exhibit 99.1 May 11, 2020 Nemaura reports positive data from early head-to-head comparison with a major incumbent CGM Device sugarBEATÒ was developed as a viable, flexible, and cost-effective alternative to invasive continuous glucose monitors (“CGM”), and the company plans to seek reimbursement in key territories. Loughborough, England, May 11, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura |
|
| May 5, 2020 |
Exhibit 99.1 May 5, 2020 Nemaura Medical Announces Interview with CEO to Air on May 11 Loughborough, England, May 5, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), to |
|
| May 5, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): May 5, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer Id |
|
| April 21, 2020 |
Exhibit 10.4 THIS NOTE (AS DEFINED BELOW) MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE ALIENATED OR ENCUMBERED WITHOUT THE PRIOR WRITTEN CONSENT OF INVESTOR (AS DEFINED BELOW). THIS NOTE IS SUBJECT TO A RIGHT OF OFFSET IN FAVOR OF INVESTOR UPON THE OCCURRENCE OF CERTAIN EVENTS AS SET FORTH IN MORE DETAIL IN SECTION 4 BELOW. State of Utah $2,000,000.00 April 15, 2020 I |
|
| April 21, 2020 |
Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of April 15, 2020, is entered into by and among NEMAURA EDICAL INC., a Nevada corporation (“Company”), DERMAL DIAGNOSTICS LIMITED, an England and Wales corporation (“Dermal Diagnostics”), TRIAL CLINIC LIMITED, an England and Wales corporation (“Trial Clinic,” and together with Dermal Diagnostics and Comp |
|
| April 21, 2020 |
Exhibit 10.3 THIS NOTE (AS DEFINED BELOW) MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE ALIENATED OR ENCUMBERED WITHOUT THE PRIOR WRITTEN CONSENT OF INVESTOR (AS DEFINED BELOW). THIS NOTE IS SUBJECT TO A RIGHT OF OFFSET IN FAVOR OF INVESTOR UPON THE OCCURRENCE OF CERTAIN EVENTS AS SET FORTH IN MORE DETAIL IN SECTION 4 BELOW. State of Utah $2,000,000.00 April 15, 2020 I |
|
| April 21, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): April 15, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| April 21, 2020 |
Exhibit 10.5 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”), dated as of April 15, 2020, is executed by Nemaura Medical Inc., a Nevada corporation (“Nemaura”), Dermal Diagnostics Limited, an England and Wales corporation (“Dermal Diagnostics”), and Trial Clinic Limited, an England and Wales corporation (“Trial Clinic,” and together with Nemaura and Dermal Diagnostics, “Debtor”), in |
|
| April 21, 2020 |
Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy Exhibit 99.1 Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy Loughborough, England, April 21, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today an |
|
| April 21, 2020 |
Exhibit 10.2 SECURED PROMISSORY NOTE Effective Date: April 15, 2020 U.S. $6,015,000.00 FOR VALUE RECEIVED, NEMAURA MEDICAL INC., a Nevada corporation (“Company”), DERMAL DIAGNOSTICS LIMITED, an England and Wales corporation (“Dermal Diagnostics”), and TRIAL CLINIC LIMITED, an England and Wales corporation (“Trial Clinic,” and together with Dermal Diagnostics, “Borrower”), jointly and severally pro |
|
| April 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for U |
|
| April 8, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): April 2, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| April 1, 2020 |
Exhibit 99.1 Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19 BEATÒ platform is planned to be extended to conditions requiring continuous temperature monitoring including viral infections and poor blood circulation to feet in persons with diabetes Loughborough, England, April 01, 2020 — Nemaura Medical Inc. (NASDAQ: N |
|
| April 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): April 1, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| April 1, 2020 |
Exhibit 99.2 Continuous Temperature Monitoring – Use in Fever Detection and Other Areas Stephen Willmor – Head of Regulatory Affairs March 2020 NASDAQ: NMRD 2 Forward - looking Statements Certain statements made in this presentation that are not historical facts constitute forward - looking statements within the mean ing of the Private Securities Litigation Reform Act of 1995. Reliance should not |
|
| March 30, 2020 |
Exhibit 99.2 Wellbeing Devices: US Market, Potential & Regulations Stephen Willmor – Head of Regulatory Affairs March 2020 NASDAQ: NMRD 2 Forward - looking Statements Certain statements made in this presentation that are not historical facts constitute forward - looking statements within the mean ing of the Private Securities Litigation Reform Act of 1995. Reliance should not be placed on forward |
|
| March 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): March 30, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| March 30, 2020 |
Exhibit 99.1 Nemaura to launch new digital brand proBEAT™ in the USA, Targeting a Market of over 100 Million potential users with its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Healthcare Subscription Service Loughborough, England, March 30, 2020 — Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing mic |
|
| March 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): March 18, 2020 NEMAURA MEDICAL INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| March 18, 2020 |
Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback Exhibit 99.1 Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback March 18, 2020, LOUGHBOROUGH, England-(BUSINESS WIRE)- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous g |
|
| March 10, 2020 |
Exhibit 99.1 MARCH 10, 2020 Nemaura Medical enters into multiple verbal non-binding agreements for its sugarBEATÒ platform sugarBEAT® strategic global partnership(s) a step closer as Nemaura Medical enters into multiple verbal non-binding agreements Loughborough, England, March 10, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on dev |
|
| March 10, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): March 10, 2020 NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employe |
|
| March 6, 2020 |
Amendment between Nemaura Medical, Inc. and Maxim Group LLC dated March 4, 2020. Exhibit 10.1 March 4, 2020 Mr. Dewan F.H. Chowdhury Chief Executive Officer Nemaura Medical Inc. 57 West 57th Street New York, New York 10019 Re: Amendment to Sales Agreement, dated October 19, 2018 Dear Mr. Chowdhury: Reference is made to that certain sales agreement, dated October 19, 2018, between Nemaura Medical Inc. (the “Company”) and Maxim Group LLC (“Maxim”) (the “Sales Agreement”). Notwit |
|
| March 6, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): March 4, 2020 NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| March 3, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): March 3, 2020 NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer |
|
| March 3, 2020 |
Exhibit 99.1 Nemaura Medical Launches sugarBEATÒ App on Play Store Ahead of its Planned Commercial Launch of BEATÒdiabetes Subscription Service sugarBEAT® App is now available on Play Store with iOS app planned to follow, ahead of the planned BEAT®diabetes subscription service launch Loughborough, England, March 3, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical |
|
| February 25, 2020 |
Exhibit 99.1 Nemaura Medical Plans Head-to-Head Study with Major Glucose Monitoring System Studies planned to compare sugarBEAT® and major continuous glucose monitor sensor, seeking to position sugarBEAT® as both a possible alternative and complementary device for people with diabetes Loughborough, England, February 25, 2020 - Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a me |
|
| February 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934 Date of Report (Date of earliest event reported): February 25, 2020 NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Empl |
|
| February 10, 2020 |
NMRD / Nemaura Medical, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2019 or ¨ TRANSITION REPORT UNDER SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: Nemaura Medical Inc. (Exact |
